association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a4 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
204 |
1 |
1 |
Tipifarnib |
Farnesyl-transferase (FNTA) |
5 |
43 |
2.77 |
1.31 |
4.24 |
2.93 |
2.4 ** |
2.5 ** |
1.7 * |
6.77e-06 |
NA |
NA |
2 |
a11 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
180 |
1 |
1 |
Thapsigargin |
sarco-endoplasmic reticulum Ca2+-ATPases |
4 |
41 |
-0.669 |
-3.89 |
0.617 |
4.5 |
2.2 ** |
2.2 ** |
2.2 ** |
1.53e-04 |
NA |
NA |
16 |
a26 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
140 |
1 |
1 |
Vinorelbine |
Microtubules |
5 |
42 |
-2.75 |
-3.88 |
-1.28 |
2.59 |
1.8 * |
1.8 * |
2 * |
4.38e-04 |
NA |
NA |
19 |
a28 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
1375 |
1 |
1 |
Temozolomide |
DNA akylating agent |
5 |
41 |
3.4 |
5.78 |
6.87 |
1.09 |
1.8 * |
1.8 * |
1.5 * |
4.74e-04 |
NA |
NA |
19 |
a29 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
201 |
1 |
1 |
Epothilone B |
Microtubules |
5 |
43 |
-3.44 |
-4.53 |
-1.71 |
2.82 |
1.8 * |
1.8 * |
1.9 * |
5.01e-04 |
NA |
NA |
19 |
a31 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
1268 |
1 |
1 |
XAV 939 |
TNKS1 (tankyrase-1) |
5 |
42 |
1.61 |
3.51 |
4.97 |
1.46 |
1.8 * |
1.8 * |
1.8 * |
5.27e-04 |
NA |
NA |
20 |
a32 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
167 |
1 |
1 |
OSU-03012 |
PDPK1 (PDK1) |
5 |
43 |
2.77 |
2.06 |
3.89 |
1.83 |
1.7 * |
1.8 * |
1.4 * |
5.71e-04 |
NA |
NA |
21 |
a38 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
1020 |
1 |
1 |
Lenalidomide |
TNFA |
5 |
40 |
1.61 |
4.13 |
5.22 |
1.08 |
1.7 * |
1.8 * |
1.4 * |
7.3e-04 |
NA |
NA |
22 |